Agonisti del Reattore GLP-1 per la Gestione dell'Obesità negli Anziani: Una Revisione di Scopo sull'Insorgenza di Sarcomazia e Obesità Sarcomatica.

PURPOSE OF REVIEW: Obesity pharmacotherapy has become increasingly relevant in older adults due to challenges in lifestyle modification and the burden of non-communicable diseases. Despite the expanding use of anti-obesity medications (AOMs), sarcopenia and sarcopenic obesity (SO) remain major concerns in this population. This review synthesizes current evidence on glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a well-studied AOMs, focusing on their effects on sarcopenia through mechanistic insights and clinical considerations in older adults. RECENT FINDINGS: GLP-1 RAs effectively induce weight loss; however, concomitant muscle mass loss is common, raising concerns about sarcopenia